Centauri Therapeutics Secures £4.3M to Propel Breakthrough Programmable Immunity and Alphamer Technology

We are excited to announce that Centauri Therapeutics Limited, a UK-based biotechnology innovator, has successfully raised £4,300,000 in new funding designed to accelerate its breakthrough research in combating life-threatening diseases. Centauri Therapeutics is at the forefront of modern drug discovery, leveraging its exemplary Alphamer technology—a cutting-edge approach based on programmable immunity. This innovative methodology involves chemically synthesised molecules that redirect naturally occurring antibodies to specific pathogens, thereby triggering a swift and targeted antibacterial immune response. By incorporating two distinct molecular components, where one end binds to a cell surface target on the pathogen using an aptamer and the other presents epitopes to engage circulating antibodies, Alphamers hold the potential to transform how bacterial infections are treated. With this infusion of capital, the company is poised to deepen its research and development efforts, further hone its platform chemistry, and expand its pipeline of promising leads. The secured funding will empower Centauri Therapeutics to bolster its preclinical programs and refine the robust intellectual property portfolio underpinning its innovative technology. This financial milestone not only underscores the confidence of investors in Centauri’s scientific vision and proprietary advancements but also sets the stage for accelerated progress towards new therapeutic solutions. As the company continues to build upon a strong foundation of granted patents and ongoing applications, it remains committed to addressing critical unmet medical needs and improving patient outcomes. This announcement marks an exciting chapter for Centauri Therapeutics as it leverages its unique technology to redefine antibacterial therapies and pave the way for a new era in biotechnology.